Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97220299

Filing Date: 01/14/2022

To the Commissioner for Trademarks:

MARK: DIAMOND (Standard Characters, see below )

The literal element of the mark consists of DIAMOND. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Vesalius Therapeutics Inc., a corporation of Delaware, having an address of
      Bldg. 600/700 Suite 7-201
      One Kendall Sq.
      Cambridge, Massachusetts 02139
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class _______: Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; software for the capture, collection, conversion, analysis, communication, processing, receiving, recording, storage and transmission of data, images, information and artificial intelligence in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for data analysis in the fields of drug discovery and healthcare, biomedical and genomic research; software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks; software for genetic assessment and identification of cancer, diseases, health status and metrics, and gene mutations for scientific, medical, diagnostic, treatment, and research purposes; software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement; scientific research, namely, research and analysis services featuring artificial intelligence and machine learning analytics in the fields of healthcare, biomedical and genomic research; research and development in the field of drug discovery and development, computational biology, bioinformatics, and genomics; research and development of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of neurological diseases and disorders, central nervous system diseases and disorders, neurodegenerative diseases and disorders, immune system-related diseases and disorders, and metabolic diseases and disorders; technical scientific consultation and product development for others in the fields of drug discovery and development, pharmaceuticals, biotechnology and immunology; consulting in the fields of drug discovery and development, clinical trial management and patient engagement in drug clinical trials
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



The owner's/holder's proposed attorney information: Christina M. Licursi. Other appointed attorneys are Michael A. Albert, Nicole Davis Amar, Michael J. Attisha, C. Hunter Baker, Jason W. Balich, Melissa Beede, Brandon S. Blackwell, Joseph M. Bowler, Kady S. Bruce, David F. Cauble, Jessica J. Chao, Tani Chen, Gitanjali Chimalakonda, Thomas S. Chlebeck, Bryan S. Conley, Gregory F. Corbett, Elizabeth A. DiMarco, Heather J. DiPietrantonio, Stuart V. Duncan Smith, Roque El-Hayek, Neil P. Ferraro, Emma L. Frank, Thomas A. Franklin, Susmita A. Gadre, Edward R. Gates, David S. Gesner, Richard F. Giunta, Matthew H. Grady, Patricia L. Granahan, Eric P. Greenwald, Philip J. Hamzik, James M. Hanifin, Jr., John S. Harmon, Jason M. Honeyman, Gerald B. Hrycyszyn, Jeffrey D. Hsi, Elisabeth H. Hunt, Robert E. Hunt, Daniel M. Huttle, Robert A. Jensen, Marc S. Johannes, Oona M. Johnstone, Quincy L. Kayton, Hunter D. Keeton, Alexandra K. Kim, Jessamine M. Lee, Kevin Y. Li, Christina M. Licursi, Helen C. Lockhart, Chelsea Loughran, Yue Matthew Ma, Kevin MacDonald, Robert T. Maldonado, Kira-Khanh McCarthy, William R. McClellan, Gabriel J. McCool, Marie A. McKiernan, Michele Moresco, James H. Morris, Elizabeth S. Mulski, Gregory S. Nieberg, Michelle K. Nyein, Timothy J. Oyer, Zachary P. Piccolomini, Michael J. Pomianek, Curtis R. Powell, Randy J. Pritzker, Michael N. Rader, Laura B. Rogers, Jonathan B. Roses, Daniel G. Rudoy, Edward J. Russavage, Eric J. Rutt, Robert N. Sahr, Anant K. Saraswat, Turhan F. Sarwar, Tonia A. Sayour, Claire E. Schuster, Karan Singh, Amanda Slade, Nathan R. Speed, Charles T. Steenburg, John L. Strand, Shirley Tan, Andrew J. Tibbetts, Maria A. Trevisan, Michael J. Twomey, John R. Van Amsterdam, Ryan M. Van Olst, Amanda L. Varrichione, Janice A. Vatland, Jessica A. vonReyn, Jessica Vosgerchian, Robert H. Walat, Patrick R.H. Waller, Edmund J. Walsh, Jennifer J. Wang, Daniel T. Wehner, John L. Welch, Adam R. Wichman, Andrew W. Williams, Douglas R. Wolf, Daniel W. Young, Lock See Yu-Jahnes, William Wei Zhang, Chelsea E. Witte-Garcia, Adam Z. Zeiger, Norman H. Zivin. Christina M. Licursi of Wolf, Greenfield & Sacks, P.C., is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      600 Atlantic Avenue
      Boston, Massachusetts 02210
      United States
      617-646-8000(phone)
      617-646-8646(fax)
      cxltrademarks@wolfgreenfield.com
The docket/reference number is F08472000300.
Christina M. Licursi submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Christina M. Licursi

PRIMARY EMAIL FOR CORRESPONDENCE: cxltrademarks@wolfgreenfield.com       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).

Declaration

Declaration Signature
The attached signature image file:
\\TICRS\EXPORT18\IMAGEOUT18\972\202\97220299\xml1\APP0003.JPG



Signatory's Name: Christopher Austin
Signatory's Position: CEO
Signatory's Phone Number: Not Provided
Signature method: Handwritten
Payment Sale Number: 97220299
Payment Accounting Date: 01/14/2022

Serial Number: 97220299
Internet Transmission Date: Fri Jan 14 16:10:32 ET 2022
TEAS Stamp: USPTO/BAS-XX.XXX.XX.XXX-2022011416103209
0192-97220299-810296d47fdab31cc408ba4183
58827bdcd525fbf93333cb59e2382b0764e907d-
CC-10304015-20220114155136496147